Open AccessInjectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence
Author(s) -
Sandra D. Comer,
Maria A. Sullivan,
Elmer Yu,
Jami L. Rothenberg,
Herbert D. Kleber,
Kyle Kampman,
Charles A. Dackis,
Charles P. O’Brien
Publication year - 2006
Publication title -
archives of general psychiatry
Language(s) - English
Resource type - Journals
eISSN - 1538-3636
pISSN - 0003-990X
DOI - 10.1001/archpsyc.63.2.210
Subject(s) - naltrexone , placebo , heroin , methadone , opioid , medicine , urine , anesthesia , narcotic antagonist , opioid antagonist , randomized controlled trial , pharmacology , (+) naloxone , drug , alternative medicine , receptor , pathology
Oral naltrexone can completely antagonize the effects produced by opioid agonists. However, poor compliance with naltrexone has been a major obstacle to the effective treatment of opioid dependence.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom